VIA
RGNX icon

Vantage Investment Advisors’s Regenxbio RGNX Stock Holding History

Vantage Investment Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$4K Sell
50
-200
-80% -$14.4K ﹤0.01% 658
2018
Q2 		$18K Buy
+250
New +$11.9K ﹤0.01% 438

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vantage Investment Advisors's RGNX Position: Q3 2018 in Review

Vantage Investment Advisors reduced its Regenxbio (RGNX) stake by 80% in Q3 2018, selling an estimated $14.4K and leaving 50 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Vantage Investment Advisors first reported a position in RGNX in Q2 2018 and has held it in 2 quarters since. The position peaked at $18K in Q2 2018. 203 funds tracked by Wall St. Rank hold RGNX as of Q3 2018.

  • Vantage Investment Advisors held 50 shares of Regenxbio worth $4K as of Q3 2018.
  • Vantage Investment Advisors sold 200 Regenxbio shares in Q3 2018, an estimated $14.4K.
  • Regenxbio made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #658 holding.
  • Vantage Investment Advisors first reported a position in Regenxbio in Q2 2018 and has held it in 2 quarters since.
  • Vantage Investment Advisors's Regenxbio position peaked at $18K in Q2 2018.
  • 203 funds tracked by Wall St. Rank held Regenxbio as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.